MPR-R significantly prolonged progression-free of charge survival as compared with MPR and MP ; the MPR and MP groups did not differ significantly regarding progression-free survival . In a prespecified landmark analysis, lenalidomide maintenance significantly prolonged progression-free survival right away of maintenance therapy in comparison with placebo . The progression-free survival advantage connected with MPR-R was consistent across all subgroups of individuals defined by stratification factors and baseline features, except those older than 75 years . Heterogeneity of treatment effects between your age subgroups was confirmed by a significant treatment-by-age interaction . Among individuals 65 to 75 years of age, MPR-R considerably prolonged progression-free survival , in comparison with MPR and MP .The researchers followed 3,999 men and 4,726 ladies from 1968-99. During the study, 936 participants created atrial fibrillation and 2,621 died without atrial fibrillation prior. Related StoriesNew findings reveal association between colorectal cancer tumor and melanoma drug treatmentMeat-rich diet may increase kidney tumor riskViralytics enters into clinical trial collaboration agreement with MSDThe researchers found that at age 40, average life time risk for atrial fibrillation was 26 % for guys and 23 % for women. At age 80, the life time risk for AF didn’t change despite fewer remaining years of existence substantially.